Currently Enrolling Heart Clinical Trials in Central Oregon

To find out which trials currently open to enrollment that you may be eligible for and how to enroll,
contact Noura Sall at 541-706-6362, Andrea Andrus at 541-706-2939.

Indication

ID

Full Title

Doctor

Status

Acute Coronary Syndrome

ROCHE dal-OUTCOMES

A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of RO4607381 on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS) McLellan Active

Rx After Heart Attack 

dal-OUTCOMES 2

A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients with Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD) McLellan Active

Heart Failure

TOPCAT

Treatment Of Preserved Cardiac function heart failure with an Aldosterone anTagonist Widmer Active

Stent

JOSTENT

Jostent Graftmaster McLellan Active

Rx After Heart Attack 

CANTOS / CACZ885M2301

A randomized, double-blind, placebo controlled, event driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP McLellan Active

Acute Coronary Syndrome

Alecardio

Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D) Noble pending





  2014 St. Charles Research
Website Design by James Web Design LLC